

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: NeuroScientific Biopharmaceuticals Limited</b>
<b>ACN: 102 832 995</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Robert Leslie McKenzie
<b>Date of last notice</b>	27 June 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Kilkenny Nominees Pty Ltd <Robert McKenzie Family A/C> <i>Director, shareholder and beneficiary</i>
<b>Date of change</b>	1 June 2026
<b>No. of securities held prior to change</b>	Kilkenny Nominees Pty Ltd <Robert McKenzie Family A/C>  5,781,475 - Ordinary Shares 3,854,317- Performance Shares  Mr Robert Leslie McKenzie- Unlisted Options exercisable at \$0.07 expiring 27 June 2028.  5,000,000 – Unlisted options

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	Performance Shares & Ordinary shares
<b>Number acquired</b>	3,854,317 – Ordinary Shares
<b>Number disposed</b>	3,854,317 – Performance Shares
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$Nil
<b>No. of securities held after change</b>	Kilkenny Nominees Pty Ltd <Robert McKenzie Family A/C> Director, shareholder and beneficiary  9,635,792 – Ordinary Shares  Mr Robert Leslie McKenzie- Unlisted Options exercisable at \$0.07 expiring 27 June 2028.  5,000,000 – Unlisted options
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Conversion of Performance Shares into Ordinary Shares, see ASX Announcement dated 26 May 2026 (the successful outcome of the SAS program satisfies the performance shares milestone as outlined in ASX Announcement dated 16 April 2025.)

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/a
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/a
<b>If prior written clearance was provided, on what date was this provided?</b>	N/a

---

+ See chapter 19 for defined terms.

For personal use only

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: NeuroScientific Biopharmaceuticals Limited</b>
<b>ACN: 102 832 995</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Paul Damien John Fry
<b>Date of last notice</b>	27 June 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Mount Royal Pty Ltd <The Fry Family Trust> <i>Director, Shareholder and Beneficiary</i>  Mr Paul Damien John Fry & Ms Gillian Laura Evans <Fry Evans Superannuation Fund A/C> <i>Beneficiary</i>
<b>Date of change</b>	1 June 2026

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>No. of securities held prior to change</b></p>	<p>Mount Royal Pty Ltd            &lt;The Fry Family Trust&gt;</p> <p>7,784,545 - Ordinary Shares            5,189,697 - Performance Shares</p> <p>Mr Paul Damien John Fry &amp; Ms Gillian Laura Evans            &lt;Fry Evans Superannuation Fund A/C&gt;</p> <p>5,698,416 - Ordinary Shares            3,798,944 - Performance Shares</p> <p>Mr Paul Damien John Fry - Unlisted Options exercisable at \$0.07 expiring 27 June 2028.</p> <p>5,000,000 – Unlisted options</p>
<p><b>Class</b></p>	<p>Performance Shares &amp;            Ordinary shares</p>
<p><b>Number acquired</b></p>	<p>8,988,641 – Ordinary Shares</p>
<p><b>Number disposed</b></p>	<p>8,988,641 – Performance Shares</p>
<p><b>Value/Consideration</b>  <small>Note: If consideration is non-cash, provide details and estimated valuation</small></p>	<p>\$Nil</p>
<p><b>No. of securities held after change</b></p>	<p>Mount Royal Pty Ltd            &lt;The Fry Family Trust&gt;</p> <p>12,974,242 – Ordinary Shares</p> <p>Mr Paul Damien John Fry &amp; Ms Gillian Laura Evans            &lt;Fry Evans Superannuation Fund A/C&gt;</p> <p>9,497,360 – Ordinary Shares</p> <p>Mr Paul Damien John Fry - Unlisted Options exercisable at \$0.07 expiring 27 June 2028.</p> <p>5,000,000 – Unlisted options</p>

+ See chapter 19 for defined terms.

For personal use only

<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Conversion of Performance Shares into Ordinary Shares, see ASX Announcement dated 26 May 2026 (the successful outcome of the SAS program satisfies the performance shares milestone as outlined in ASX Announcement dated 16 April 2025.)</p>
---	--

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/a
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/a
<b>If prior written clearance was provided, on what date was this provided?</b>	N/a

<sup>+</sup> See chapter 19 for defined terms.

For personal use only

For personal use only

---

+ See chapter 19 for defined terms.